Related donor hematopoietic stem cell transplantation for Fanconi anemia without radiation: A single center experience in Turkey

被引:11
作者
Ertem, Mehmet [1 ]
Ileri, Talia [1 ]
Azik, Fatih [1 ]
Uysal, Zumrut [1 ]
Gozdasoglu, Sevgi [1 ]
机构
[1] Ankara Univ, Sch Med, Dept Pediat Hematol, TR-06100 Ankara, Turkey
关键词
Fanconi anemia; stem cell transplantation; non-irradiation; related donor; fludarabine; conditioning regimen; BONE-MARROW-TRANSPLANTATION; FLUDARABINE-BASED PROTOCOL; ACQUIRED APLASTIC-ANEMIA; MATCHED SIBLING DONORS; VERSUS-HOST-DISEASE; UNRELATED DONORS; GRAFT; CYCLOPHOSPHAMIDE; LEUKEMIA; SEATTLE;
D O I
10.1111/j.1399-3046.2008.00952.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Eight children with FA underwent allogeneic HSCT without using irradiation for the conditioning regimen. Patients received two different conditioning regimens: first two patients received BU 1.5 mg/kg/day for four days and CY 10 mg/kg/day for four days and the other regimen was: Flu 30 mg/m(2)/day for five days, CY 10 mg/kg/day for two days, and ATG-Fresenius 9-10 mg/kg/day for four days. GVHD prophylaxis consisted of CsA + MTX for the first two patients and only CsA for the others. All patients received HLA-identical stem cells from related donors. Primary engraftment was demonstrated in all patients. No patient developed acute GVHD and one patient had chronic GVHD. Only one patient who received BU based regimen died because of VOD. Overall, seven patients (87.5%) are alive with stable full donor chimerism at a median follow-up time of 2.5 yr (range: 1.7-8.9 yr). None of the patients developed secondary malignancy. Based on our data, we conclude that Flu-based, non-irradiation conditioning regimen was safe with low organ toxicity and stable engraftment in FA patients undergoing HSCT from matched related donors.
引用
收藏
页码:88 / 95
页数:8
相关论文
共 45 条
[1]   Long-term outcome after bone marrow transplantation for severe aplastic anemia [J].
Ades, L ;
Mary, JY ;
Robin, M ;
Ferry, C ;
Porcher, R ;
Esperou, H ;
Ribaud, P ;
Devergie, A ;
Traineau, R ;
Gluckman, E ;
Socié, G .
BLOOD, 2004, 103 (07) :2490-2497
[2]   Fludarabine-based protocol for human umbilical cord blood transplantation in children with fanconi anemia [J].
Aker, M ;
Varadi, G ;
Slavin, S ;
Nagler, A .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1999, 21 (03) :237-239
[3]  
ALTER BP, 2003, HEMATOLOGY INFANCY C, P280
[4]   Fanconi anemia [J].
Bagby, Grover C. ;
Alter, Blanche P. .
SEMINARS IN HEMATOLOGY, 2006, 43 (03) :147-156
[5]   REGIMEN-RELATED TOXICITY IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].
BEARMAN, SI ;
APPELBAUM, FR ;
BUCKNER, CD ;
PETERSEN, FB ;
FISHER, LD ;
CLIFT, RA ;
THOMAS, ED .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) :1562-1568
[6]  
BERGER R, 1980, BRIT J HAEMATOL, V45, P565, DOI 10.1111/j.1365-2141.1980.tb07179.x
[7]   Malignant neoplasms following bone marrow transplantation [J].
Bhatia, S ;
Ramsay, NKC ;
Steinbuch, M ;
Dusenbery, KE ;
Shapiro, RS ;
Weisdorf, DJ ;
Robison, LL ;
Miller, JS ;
Neglia, JP .
BLOOD, 1996, 87 (09) :3633-3639
[8]   Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors [J].
Bitan, M. ;
Or, R. ;
Shapira, M. Y. ;
Aker, M. ;
Resnick, I. B. ;
Ackerstein, A. ;
Samuel, S. ;
Elad, S. ;
Slavin, S. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (07) :712-718
[9]   Solid cancers after bone marrow transplantation [J].
Curtis, RE ;
Rowlings, PA ;
Deeg, HJ ;
Shriner, DA ;
Socie, G ;
Travis, LB ;
Horowitz, MM ;
Witherspoon, RP ;
Hoover, RN ;
Sobocinski, KA ;
Fraumeni, JF ;
Boice, JD .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (13) :897-904
[10]   Non-TBI stem cell transplantation protocol for Fanconi anaemia using HLA-compatible sibling and unrelated donors [J].
de la Fuente, J ;
Reiss, S ;
McCloy, M ;
Vulliamy, T ;
Roberts, IAG ;
Rahemtulla, A ;
Dokal, I .
BONE MARROW TRANSPLANTATION, 2003, 32 (07) :653-656